Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.

You may also be interested in...



GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies

Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.

GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies

Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.

2008 Deals Of The Year

Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY

Related Content

Topics

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel